Ascendis Pharma A/S (ASND)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

Revenue Quarterly

0 90M 180M 270M Q1 '17: 372K Q2 '17: 444K Q3 '17: 434K Q4 '17: 280K Q1 '18: 28K Q2 '18: 18K Q3 '18: 20K Q4 '18: 10.5M Q1 '19: 5.4M Q2 '19: 3.2M Q3 '19: 2.2M Q4 '19: 2.5M Q1 '20: 2.2M Q2 '20: 1.4M Q3 '20: 2.8M Q4 '20: 535K Q1 '21: 746K Q2 '21: 1M Q3 '21: 1.1M Q4 '21: 4.9M Q1 '22: 6.8M Q2 '22: 6.2M Q3 '22: 15.3M Q4 '22: 22.9M Q1 '23: 33.6M Q2 '23: 47.4M Q3 '23: 48M Q4 '23: 137.7M Q1 '24: 95.9M Q2 '24: 36M Q3 '24: 57.8M Q4 '24: 173.9M Q1 '25: 101M Q2 '25: 158M Q3 '25: 213.6M Q4 '25: 247.5M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Gross Profit Quarterly

0 80M 160M 240M Q1 '21: 746K Q2 '21: 1M Q3 '21: 1.1M Q4 '21: 1.4M Q1 '22: 2.6M Q2 '22: 5.1M Q3 '22: 13.6M Q4 '22: 17.8M Q1 '23: 29M Q2 '23: 34.5M Q3 '23: 40.6M Q4 '23: 118.2M Q1 '24: 88.3M Q2 '24: 24.5M Q3 '24: 46.6M Q4 '24: 159.9M Q1 '25: 83.4M Q2 '25: 126.6M Q3 '25: 191.3M Q4 '25: 223.9M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q1 '17: -23.6M Q2 '17: -24.7M Q3 '17: -31.5M Q4 '17: -31.8M Q1 '18: -35.2M Q2 '18: -45.4M Q3 '18: -38.3M Q4 '18: -35.9M Q1 '19: -56.3M Q2 '19: -51.6M Q3 '19: -54M Q4 '19: -64.8M Q1 '20: -73.2M Q2 '20: -82.9M Q3 '20: -78.8M Q4 '20: -95.6M Q1 '21: -124.7M Q2 '21: -117.6M Q3 '21: -96.9M Q4 '21: -112.6M Q1 '22: -128M Q2 '22: -141.9M Q3 '22: -144.5M Q4 '22: -147.4M Q1 '23: -143.7M Q2 '23: -140.8M Q3 '23: -134.4M Q4 '23: -36.6M Q1 '24: -49.1M Q2 '24: -133.3M Q3 '24: -96.7M Q4 '24: 383K Q1 '25: -104.2M Q2 '25: -53M Q3 '25: 11M Q4 '25: 9.9M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Net Income Quarterly

-240M -160M -80M 0 80M 160M 240M Q1 '17: -25.1M Q2 '17: -30.7M Q3 '17: -33.9M Q4 '17: -34.2M Q1 '18: -41.4M Q2 '18: -22.8M Q3 '18: -34M Q4 '18: -32M Q1 '19: -53.6M Q2 '19: -58.9M Q3 '19: -25.1M Q4 '19: -80.4M Q1 '20: -63.3M Q2 '20: -94.9M Q3 '20: -121.7M Q4 '20: -139M Q1 '21: -62.8M Q2 '21: -134.4M Q3 '21: -80.3M Q4 '21: -106.1M Q1 '22: -125.5M Q2 '22: -81.3M Q3 '22: -169M Q4 '22: -207.4M Q1 '23: -110.9M Q2 '23: -121.4M Q3 '23: -162.2M Q4 '23: -86.9M Q1 '24: -131M Q2 '24: -109.4M Q3 '24: -99.2M Q4 '24: -38.5M Q1 '25: -94.6M Q2 '25: -38.9M Q3 '25: -61M Q4 '25: -33.6M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Cost of Revenue Quarterly

0 15M 30M 45M Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 3.5M Q1 '22: 4.2M Q2 '22: 1.1M Q3 '22: 1.7M Q4 '22: 5.1M Q1 '23: 4.6M Q2 '23: 12.9M Q3 '23: 7.4M Q4 '23: 19.5M Q1 '24: 7.6M Q2 '24: 11.5M Q3 '24: 11.2M Q4 '24: 14M Q1 '25: 17.5M Q2 '25: 31.4M Q3 '25: 22.4M Q4 '25: 23.6M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating Cash Flow Quarterly

-180M -120M -60M 0 60M 120M 180M Q1 '17: -21.2M Q2 '17: -23.9M Q3 '17: -25.8M Q4 '17: -24.2M Q1 '18: -36.7M Q2 '18: -20.1M Q3 '18: -46.4M Q4 '18: -35.6M Q1 '19: -60.9M Q2 '19: -5.9M Q3 '19: -59.9M Q4 '19: -49.2M Q1 '20: -66.8M Q2 '20: -56.6M Q3 '20: -57.8M Q4 '20: -90.3M Q1 '21: -81.6M Q2 '21: -115.2M Q3 '21: -97.5M Q4 '21: -123.3M Q1 '22: -130.8M Q2 '22: -124.4M Q3 '22: -98.8M Q4 '22: -141.7M Q1 '23: -147M Q2 '23: -153.1M Q3 '23: -124.7M Q4 '23: -42.5M Q1 '24: -101.6M Q2 '24: -61.3M Q3 '24: -56.1M Q4 '24: -87.2M Q1 '25: -14.3M Q2 '25: -7.3M Q3 '25: 2.2M Q4 '25: 73.4M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Free Cash Flow Quarterly

-180M -120M -60M 0 60M 120M 180M Q1 '17: -21.6M Q2 '17: -24.1M Q3 '17: -25.9M Q4 '17: -24.4M Q1 '18: -36.8M Q2 '18: -20.4M Q3 '18: -47.5M Q4 '18: -36.6M Q1 '19: -63.3M Q2 '19: -6.2M Q3 '19: -61.2M Q4 '19: -50.4M Q1 '20: -72.9M Q2 '20: -61.2M Q3 '20: -62.7M Q4 '20: -94.6M Q1 '21: -85.6M Q2 '21: -118.8M Q3 '21: -108.8M Q4 '21: -128.1M Q1 '22: -134.6M Q2 '22: -128.1M Q3 '22: -102M Q4 '22: -145.5M Q1 '23: -148.1M Q2 '23: -153.6M Q3 '23: -125.7M Q4 '23: -42.5M Q1 '24: -101.8M Q2 '24: -61.6M Q3 '24: -56.6M Q3 '17 Q3 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '17: 32.4M Q2 '17: 32.5M Q3 '17: 32.6M Q1 '18: 38.7M Q2 '18: 41.7M Q3 '18: 41.9M Q1 '19: 43.4M Q2 '19: 47.2M Q3 '19: 47.6M Q1 '20: 48M Q2 '20: 48.2M Q3 '20: 52.7M Q1 '21: 53.8M Q2 '21: 53.8M Q3 '21: 54.6M Q1 '22: 56.7M Q2 '22: 55.8M Q3 '22: 55.8M Q1 '23: 56.1M Q2 '23: 56.2M Q3 '23: 56.3M Q1 '24: 56.9M Q2 '24: 60.8M Q3 '24: 57.5M Q1 '25: 60M Q2 '25: 63.9M Q3 '25: 60.8M Q3 '17 Q1 '19 Q2 '20 Q3 '21 Q1 '23 Q2 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-12.00 -8.00 -4.00 0.00 4.00 8.00 12.00 Q4 '22: -10.40 Q1 '23: -10.17 Q2 '23: -10.87 Q3 '23: -10.72 Q4 '23: -8.55 Q1 '24: -8.87 Q2 '24: -8.62 Q3 '24: -7.46 Q4 '24: -6.53 Q1 '25: -5.81 Q2 '25: -4.54 Q3 '25: -3.82 Q4 '25: -3.76 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.